Clinical Trial Update: Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of celecoxib and docetaxel in patients with non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Celecoxib (Celecoxib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED